Evidence map›Paper›PMID 38539425›Full record

ArticleCancers2024

Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma.

Fereshteh Yousefirizi, Claire Gowdy, Ivan S Klyuzhin, Maziar Sabouri, Petter Tonseth, Anna R Hayden, Donald Wilson, Laurie H Sehn, David W Scott, Christian Steidl and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Semiquantitative 2-[Frontiers in medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Fereshteh YousefiriziDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Claire GowdyBC Children's Hospital, Vancouver, BC V6H 3N1, Canada.ORCID 0009-0008-8054-0635
Ivan S KlyuzhinDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Maziar SabouriDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Petter TonsethDivision of Radiology, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Anna R HaydenCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Donald WilsonDivision of Radiology, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Laurie H SehnCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
David W ScottCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Christian SteidlCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Kerry J SavageCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Carlos F UribeDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0003-3127-7478
Arman RahmimDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Spinal Cord Injury BC · CAUniversity of British Columbia · CABC Children's Hospital · CA

Funding

CIHR PJT-173231
6 · The paper itself

Abstract

objectivesAccurate outcome prediction is important for making informed clinical decisions in cancer treatment. In this study, we assessed the feasibility of using changes in radiomic features over time (Delta radiomics: absolute and relative) following chemotherapy, to predict relapse/progression and time to progression (TTP) of primary mediastinal large B-cell lymphoma (PMBCL) patients. MATERIAL AND

methodsGiven the lack of standard staging PET scans until 2011, only 31 out of 103 PMBCL patients in our retrospective study had both pre-treatment and end-of-treatment (EoT) scans. Consequently, our radiomics analysis focused on these 31 patients who underwent [

resultsTo predict relapse/progression using Delta radiomics between the baseline (staging) and EoT scans, the best performances in terms of accuracy and F1 score (F1 score is the harmonic mean of precision and recall, where precision is the ratio of true positives to the sum of true positives and false positives, and recall is the ratio of true positives to the sum of true positives and false negatives) were achieved with ICARE (accuracy = 0.81 ± 0.15, F1 = 0.77 ± 0.18), RF (accuracy = 0.89 ± 0.04, F1 = 0.87 ± 0.04), and LDA (accuracy = 0.89 ± 0.03, F1 = 0.89 ± 0.03), that are higher compared to the predictive power achieved by using only EoT radiomics features. For the second category of our analysis, TTP prediction, the best performer was CoxNet (LASSO feature selection) with c-index = 0.67 ± 0.06 when using baseline + Delta features (inclusion of both baseline and Delta features). The TTP results via Delta radiomics were comparable to the use of radiomics features extracted from EoT scans for TTP analysis (c-index = 0.68 ± 0.09) using CoxNet (with SFS). The performance of Deauville Score (DS) for TTP was c-index = 0.66 ± 0.09 for n = 50 and 0.67 ± 03 for n = 31 cases when using EoT scans with no significant differences compared to the radiomics signature from either EoT scans or baseline + Delta features (

conclusionThis work demonstrates the potential of Delta radiomics and the importance of using EoT scans to predict progression and TTP from PMBCL [

Indexed as

18F-FDG PET/CTmachine learningPrimary Mediastinal Large B-cell Lymphomaprogression predictionradiomicstime to progression

Identifiers

PMID38539425
PMCPMC10968861
OpenAlexW4392595924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.